Late relapse of chronic myeloid leukemia after allogeneic stem cell tranplan
Journal Title: OncoReview - Year 2012, Vol 2, Issue 4
Abstract
Chronic myeloid leukemia now is a disease which in the most cases is well manageable with tyrosine kinase inhibitors treatment. Still however the only potentially curable therapeutic approach is for chronic myeloid leukemia allogeneic stem cell transplantation. 30-years old woman was diagnosed as a relapse 18 years after sibling matched donor allotransplantation. After a short cytoreductive treatment imatinib was given in standard dose. Then due to hematological toxicities the dose was diminished to 100 mg. The patient has maintained major molecular response since 2,5 years.
Authors and Affiliations
Ryszard Wichary
Keywords
Related Articles
- EP ID EP53188
- DOI -
- Views 236
- Downloads 0
Ifosfamide-induced encephalopathy in a patient with metastatic fibrosarcoma
Ifosfamide is a cytostatic drug commonly used in chemotherapy. One of the common adverse effects resulting from the treatment with ifosfamide is encephalopathy. This paper describes a case study of a 64-year-old patient...
The role of lapatinib in HER2-positive breast cancer
HER2 positive breast cancer presents 25–35% of newly diagnosed cases and is associated with more aggressiveness and poorer prognosis. The anti-HER2 monoclonal antibody trastuzumab improved the outcome of women with HER p...
Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin
Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disea...
Compliance, adherence, persistence – przyczyny i konsekwencje niestosowania się pacjentów do zaleceń terapeutycznych
Nieprzestrzeganie zaleceń terapeutycznych znajduje się wśród najpoważniejszych problemów zdrowotnych ludzkości. Zostało uznane za jedną z najważniejszych przeszkód w osiąganiu korzyści z terapii opartej na aktualnej wied...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...